Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease

European Journal of Clinical Investigation

Volumn 44, Issue 3, 2014, Pages 276-284

  Almquist, Tora ^a,b   Jacobson, Stefan H ^b   Mobarrez, Fariborz ^b   Näsman, Per ^c   Hjemdahl, Paul ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Chronic kidney disease; Diabetes mellitus; Inflammation; Lipid lowering treatment

Indexed keywords

CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; INFLAMMATION; LIPID-LOWERING TREATMENT;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CROSS-OVER STUDIES; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84893736247     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12230     Document Type: Article

References (40)

1. Executive summary: standards of medical care in diabetes-2010. Diab Care 2010;33:4-10.
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.
3. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-95.
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
5. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353:1649-52.
6. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004;43:244-53.
7. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88:1121-7.
8. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol 2010;134:33-46.
9. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006;17:368-77.
10. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
11. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
12. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157:263-75.
13. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92.
14. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003;24:225-48.
15. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79:620-9.
16. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol 2010;633:62-70.
17. Almquist T, Jacobson SH, Lins PE, Farndale RW, Hjemdahl P. Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial. Nephrol Dial Transplant 2012;27:3540-6.
18. Levey AS, Bosch JP, Lewis JB, Green T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
19. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
20. McLaren JE, Ramji DP. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev 2009;20:125-35.
21. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004;95:858-66.
22. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31:969-79.
23. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004;109:18-26.
24. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004;110:3687-92.
25. Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Kim DS et al. Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. Atherosclerosis 2004;177:147-53.
26. Miura S, Saku K. Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med 2008;47:1165-70.
27. Seedorf U, Engel T, Lueken A, Bode G, Lorkowski S, Assmann G. Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem Biophys Res Commun 2004;320:1337-41.
28. Gomez-Garre D, Munoz-Pacheco P, Gonzalez-Rubio ML, Aragoncillo P, Granados R, Fernandez-Cruz A. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol 2009;156:1218-27.
29. Krysiak R, Okopien B. The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmacol 2011;57:505-12.
30. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011;7:327-40.
31. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000;15:1624-30.
32. Stach K, Nguyen XD, Lang S, Elmas E, Weiss C, Borggrefe M et al. Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand. Cardiol J 2012;19:20-8.
33. Rosario RF, Prabhakar S. Lipids and diabetic nephropathy. Curr Diab Rep 2006;6:455-62.
34. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260-9.
35. Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 2011;18:1018-28.
36. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 2012;30:49-59.
37. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000;58:1492-9.
38. Titan SM, Vieira JM Jr, Dominguez WV, Moreira SR, Pereira AB, Barros RT et al. Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy. J Diabetes Complications 2012;26:546-53.
39. El Mesallamy HO, Ahmed HH, Bassyouni AA, Ahmed AS. Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy. Clin Biochem 2012;45:646-50.
40. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208-19.